ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
John P. Neoptolemos(University of Verona), Markus W. Büchler(University of Verona), Deborah Stocken(University of Verona), Paula Ghaneh(University of Verona), Daniel J. Smith(University of Verona), Claudio Bassi(University of Verona), Malcolm Moore(University of Verona), David Cunningham(University of Verona), Christos Dervenis(University of Verona), D. Goldstein(University of Verona), The European Study Group for Pancreatic Cancer (ESPAC)
Cited by 73
Abstract
LBA4505 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Related Papers
No related papers found
Powered by citation graph analysis